PTC Therapeutics, Inc.
PTCT
$71.70
-$0.27-0.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 228.75% | -100.32% | -104.85% | 114.90% | 34.61% |
| Total Depreciation and Amortization | 109.34% | 113.45% | 90.75% | 71.28% | 8.05% |
| Total Amortization of Deferred Charges | 27.15% | 2.01% | 1.95% | 1.67% | 2.37% |
| Total Other Non-Cash Items | 24.89% | 1.70% | 53.19% | -166.97% | -51.41% |
| Change in Net Operating Assets | 160.93% | -163.06% | 149.09% | -963.26% | -49.58% |
| Cash from Operations | 321.34% | -106.79% | -14.23% | 13.89% | 18.36% |
| Capital Expenditure | -75.78% | 30.57% | 36.98% | -559.96% | -116.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.25% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 71.39% | 49.35% | -86.60% | -578.61% | -315.15% |
| Cash from Investing | 70.96% | 49.16% | -87.30% | -578.67% | -540.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 313.96% | -59.35% | 136.12% | 2,837.17% | -15.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -100.00% |
| Cash from Financing | 5,249.10% | -31.96% | 1,042.78% | 186.34% | -98.39% |
| Foreign Exchange rate Adjustments | -118.68% | -128.26% | 213.20% | -170.99% | 361.96% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 146.65% | -121.11% | 22.11% | -169.33% | -545.34% |